#USA #Princeton #SAP-001 #Shanton Pharma #hyperuricemia

Shanton Pharma Achieves Milestones in Pediatric Study Waivers

Shanton Pharma, a clinical-stage biotechnology company, has made significant strides in the development of its innovative treatment, SAP-001, for hyperuricemia and gout in adults. Recently, the company announced that it has received waivers from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), exempting it from conducting pediatric clinical studies for SAP-001. This marks a notable achievement in the regulatory landscape, streamlining the path to market for this promising therapy.

Waivers Granted by EMA and FDA

On November 11, 2026, Shanton Pharma revealed that the EMA had granted a product-specific waiver for all pediatric age groups with hyperuricemia, except those caused by chronic kidney disease or obesity. This decision was preceded by similar agreement from the FDA, which recognizes the rarity of gout among children and has accordingly exempted SAP-001 from pediatric study requirements.

Bing Li, Ph.D., Shanton Pharma’s Chief Executive Officer, expressed satisfaction with the regulatory bodies’ decisions, highlighting that these waivers significantly diminish the administrative burdens and financial costs associated with clinical trials. He stated, "We are pleased that the EMA and FDA have determined that pediatric clinical studies evaluating SAP-001 are not needed to support market authorization applications for hyperuricemia and gout."

Implications for Shanton Pharma

The granted waivers allow Shanton Pharma to focus its resources on advancing the development of SAP-001 without the added complexity and expense of pediatric trials. This strategic opportunity is further reinforced by input from Robert Terkeltaub, M.D., a renowned Professor Emeritus of Medicine at UCSD, who noted that these waivers pave the way for bringing a first-in-class oral urate-lowering therapy to patients struggling with gout not adequately addressed by existing treatments.

SAP-001 is designed to provide a once-a-day oral solution for those affected by uncontrolled and refractory gout. Its unique mechanism of action positions it as a promising alternative within the treatment landscape. During a recent Phase 2b study, SAP-001 demonstrated superior efficacy and safety compared to current standard care options, particularly in patients resistant to traditional therapies.

Fast Track Designation and Future Prospects

Shanton Pharma’s commitment to innovative solutions didn’t go unnoticed, as the FDA awarded SAP-001 Fast Track designation last year. This designation acknowledges the drug's potential to significantly address the substantial unmet medical needs surrounding uncontrolled gout, a condition often challenging to manage with current available therapies.

The journey of Shanton Pharma since its inception in 2016 exemplifies the entrepreneurial spirit in biotech, addressing critical health issues impacting many lives. Headquartered in Singapore, with an international R&D presence spanning the USA and China, the company is set on a path to redefine treatment options for hyperuricemia and gout.

With the regulatory hurdles lowered and a proactive development strategy in place, Shanton Pharma is poised to revolutionize how hidden conditions like gout are treated. The waivers received reflect not only a regulatory victory but also a promising future for SAP-001 as it advances closer to becoming a valuable option for physicians and patients alike.

For more information about Shanton Pharma and its ongoing research, visit their official website.